Table 2.
Univariate analysis of the concordance rate between WFO and the GMDT.
| Concordance (n = 27) | Discordance (n = 38) | p | |
|---|---|---|---|
| Age | 59.1 ± 12.3 | 62.0 ± 11.2 | 0.49 |
| Sex | 0.52 | ||
| Male | 17 (63.0%) | 27 (71.1%) | |
| Female | 10 (37.0%) | 11 (28.9%) | |
| BMI | 20.9 ± 3.6 | 21.6 ± 3.8 | 0.53 |
| Chemotherapy | 0.89 | ||
| Adjuvant chemotherapy | 14(51.9%) | 19(50.0%) | |
| Palliative chemotherapy | 13(48.1%) | 19(50.0%) | |
| R resection | 0.13 | ||
| R0 | 19 (70.4%) | 22 (57.9%) | |
| R1 | 1 (3.7%) | 1 (2.6%) | |
| R2 | 2 (7.4%) | 0 (0.0%) | |
| HER2+ | 4 | 5 | 0.83 |
| Stage | < 0.01 | ||
| II | 6 (22.2%) | 15 (39.5%) | |
| III | 15 (55.6%) | 4 (10.5%) | |
| IV or recurrent | 6 (22.2%) | 19 (50.0%) | |
| Performance | 0.71 | ||
| ECOG 0, 1 | 25 (92.6%) | 34 (89.5%) | |
| ECOG 2, 3 | 2 (7.4%) | 4 (10.5%) |
BMI, body mass index; HER2/neu, human epidermal growth factor receptor; ECOG,Eastern Cooperative Oncology Group.